title: Is peripartum zidovudine absolutely necessary for patients with a viral load less than 1,000 copies/ml?
abstract: Late access to obstetrics service, viral load of >1,000 copies/ml and short duration antenatal highly active antiretroviral treatment (HAART), are the strongest predictors for mother-to-child transmission (MTCT). Neonatal triple therapy did not seem to reduce MTCT if the above risk factors were present. Intrapartum intravenous zidovudine (i.v. ZDV) of <4 h does not seem to increase the risk of MTCT if the viral load is <1,000 in those receiving HAART. Intrapartum i.v. ZDV >4 h did not seem to reduce the risk of MTCT with the viral load >1,000 in patients having <4 weeks of HAART.
authors.affiliation: Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Republic of Ireland. vuivunwong@yahoo.com
authors.forename: V V
authors.initials: VV
authors.lastname: Wong
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control* / Q000706:statistics & numerical data; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D011295:Prenatal Care / Q000379:methods; D012307:Risk Factors; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine